echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The country's first fabre treatment drug! Sanofi injections are approved for sale with Agaglyse beta.

    The country's first fabre treatment drug! Sanofi injections are approved for sale with Agaglyse beta.

    • Last Update: 2020-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Fabre disease is a congenital metabolic disease caused by The X-chain gene defect, which manifests itself as a significant decrease or loss of the activity of alpha-semilaccosidease abody in the patient's body, resulting in the pathological accumulation of glycolipids in the lysosomes of various tissue cells.
    the disease originated in the fetus and accompanied by the patient's gradual deterioration throughout life, causing the failure of heart, kidney and other important organs.
    2018 the disease is included in the country's first list of rare diseases, is a serious life-threatening disease and there is no effective treatment in the country.
    injection of Agaglyse beta is sanofi (China) Investment Co., Ltd. agent Genzyme Europe B.V. to declare, and was included in the country's second batch of clinically urgently needed new drugs list.
    the State Drug Administration shall, in accordance with the relevant provisions of the Notice on Optimizing the Review and Approval of Drug Registration, incorporate it into the priority review of the varieties and approve its import registration application in accordance with the data of overseas clinical trials and the characteristics of the product in the light of the validity and safety characteristics of the product.
    approved listing of this product will bring good news to the treatment of patients with domestic law.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.